266 related articles for article (PubMed ID: 28263712)
1. Synergistic blockade of alcohol escalation drinking in mice by a combination of novel kappa opioid receptor agonist Mesyl Salvinorin B and naltrexone.
Zhou Y; Crowley RS; Ben K; Prisinzano TE; Kreek MJ
Brain Res; 2017 May; 1662():75-86. PubMed ID: 28263712
[TBL] [Abstract][Full Text] [Related]
2. Effects of mesyl salvinorin B alone and in combination with naltrexone on alcohol deprivation effect in male and female mice.
Zhou Y; Crowley R; Prisinzano T; Kreek MJ
Neurosci Lett; 2018 Apr; 673():19-23. PubMed ID: 29496608
[TBL] [Abstract][Full Text] [Related]
3. Clinically utilized kappa-opioid receptor agonist nalfurafine combined with low-dose naltrexone prevents alcohol relapse-like drinking in male and female mice.
Zhou Y; Kreek MJ
Brain Res; 2019 Dec; 1724():146410. PubMed ID: 31469985
[TBL] [Abstract][Full Text] [Related]
4. Combination of Clinically Utilized Kappa-Opioid Receptor Agonist Nalfurafine With Low-Dose Naltrexone Reduces Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Kreek MJ
Alcohol Clin Exp Res; 2019 Jun; 43(6):1077-1090. PubMed ID: 30908671
[TBL] [Abstract][Full Text] [Related]
5. Pharmacology and anti-addiction effects of the novel κ opioid receptor agonist Mesyl Sal B, a potent and long-acting analogue of salvinorin A.
Simonson B; Morani AS; Ewald AW; Walker L; Kumar N; Simpson D; Miller JH; Prisinzano TE; Kivell BM
Br J Pharmacol; 2015 Jan; 172(2):515-31. PubMed ID: 24641310
[TBL] [Abstract][Full Text] [Related]
6. V1b Receptor Antagonist SSR149415 and Naltrexone Synergistically Decrease Excessive Alcohol Drinking in Male and Female Mice.
Zhou Y; Rubinstein M; Low MJ; Kreek MJ
Alcohol Clin Exp Res; 2018 Jan; 42(1):195-205. PubMed ID: 29105118
[TBL] [Abstract][Full Text] [Related]
7. Hypothalamic-specific proopiomelanocortin deficiency reduces alcohol drinking in male and female mice.
Zhou Y; Rubinstein M; Low MJ; Kreek MJ
Genes Brain Behav; 2017 Apr; 16(4):449-461. PubMed ID: 27870313
[TBL] [Abstract][Full Text] [Related]
8. Effects of oral loperamide on efficacy of naltrexone, baclofen and AM-251 in blocking ethanol self-administration in rats.
Dean RL; Eyerman D; Todtenkopf MS; Turncliff RZ; Bidlack JM; Deaver DR
Pharmacol Biochem Behav; 2012 Jan; 100(3):530-7. PubMed ID: 22056608
[TBL] [Abstract][Full Text] [Related]
9. The novel mu-opioid antagonist, GSK1521498, reduces ethanol consumption in C57BL/6J mice.
Ripley TL; Sanchez-Roige S; Bullmore ET; Mugnaini M; Maltby K; Miller SR; Wille DR; Nathan P; Stephens DN
Psychopharmacology (Berl); 2015 Sep; 232(18):3431-41. PubMed ID: 26141191
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in the effect of bupropion and naltrexone combination on alcohol drinking in mice.
Zhou Y; Leri F; Low MJ; Kreek MJ
Pharmacol Biochem Behav; 2019 Jun; 181():28-36. PubMed ID: 30991059
[TBL] [Abstract][Full Text] [Related]
11. Effects of selective opioid receptor antagonists on alcohol-induced and nicotine-induced antinociception.
Campbell VC; Taylor RE; Tizabi Y
Alcohol Clin Exp Res; 2007 Aug; 31(8):1435-40. PubMed ID: 17550364
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological evidence for a motivational role of kappa-opioid systems in ethanol dependence.
Walker BM; Koob GF
Neuropsychopharmacology; 2008 Feb; 33(3):643-52. PubMed ID: 17473837
[TBL] [Abstract][Full Text] [Related]
13. Kappa Opioid Receptor Agonist Mesyl Sal B Attenuates Behavioral Sensitization to Cocaine with Fewer Aversive Side-Effects than Salvinorin A in Rodents.
Kivell BM; Paton KF; Kumar N; Morani AS; Culverhouse A; Shepherd A; Welsh SA; Biggerstaff A; Crowley RS; Prisinzano TE
Molecules; 2018 Oct; 23(10):. PubMed ID: 30314288
[TBL] [Abstract][Full Text] [Related]
14. Continuous delivery of naltrexone and nalmefene leads to tolerance in reducing alcohol drinking and to supersensitivity of brain opioid receptors.
Korpi ER; Linden AM; Hytönen HR; Paasikoski N; Vashchinkina E; Dudek M; Herr DR; Hyytiä P
Addict Biol; 2017 Jul; 22(4):1022-1035. PubMed ID: 26990998
[TBL] [Abstract][Full Text] [Related]
15. Hypericum perforatum CO2 extract and opioid receptor antagonists act synergistically to reduce ethanol intake in alcohol-preferring rats.
Perfumi M; Santoni M; Cippitelli A; Ciccocioppo R; Froldi R; Massi M
Alcohol Clin Exp Res; 2003 Oct; 27(10):1554-62. PubMed ID: 14574225
[TBL] [Abstract][Full Text] [Related]
16. The serotonin 2C receptor agonist lorcaserin, alone and in combination with the opioid receptor antagonist naltrexone, attenuates binge-like ethanol drinking.
Tabbara RI; Li Z; Fletcher PJ; Lê AD
Addict Biol; 2021 Sep; 26(5):e13040. PubMed ID: 33928736
[TBL] [Abstract][Full Text] [Related]
17. Dissociation of μ-opioid receptor and CRF-R1 antagonist effects on escalated ethanol consumption and mPFC serotonin in C57BL/6J mice.
Hwa LS; Shimamoto A; Kayyali T; Norman KJ; Valentino RJ; DeBold JF; Miczek KA
Addict Biol; 2016 Jan; 21(1):111-24. PubMed ID: 25262980
[TBL] [Abstract][Full Text] [Related]
18. [Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].
Kato H
Nihon Arukoru Yakubutsu Igakkai Zasshi; 2008 Oct; 43(5):697-704. PubMed ID: 19068776
[TBL] [Abstract][Full Text] [Related]
19. Opioidergic modulation of ethanol self-administration in the ventral pallidum.
Kemppainen H; Raivio N; Suo-Yrjo V; Kiianmaa K
Alcohol Clin Exp Res; 2012 Feb; 36(2):286-93. PubMed ID: 21895714
[TBL] [Abstract][Full Text] [Related]
20. The Novel μ-Opioid Receptor Antagonist GSK1521498 Decreases Both Alcohol Seeking and Drinking: Evidence from a New Preclinical Model of Alcohol Seeking.
Giuliano C; Goodlett CR; Economidou D; García-Pardo MP; Belin D; Robbins TW; Bullmore ET; Everitt BJ
Neuropsychopharmacology; 2015 Dec; 40(13):2981-92. PubMed ID: 26044906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
